A phase Ia/Ib, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors
- Conditions
- Cancer (solid tumors)10027476
- Registration Number
- NL-OMON53927
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 4
1. Provision of signed and dated, written informed consent form ICF in
accordance with ICH-GCP and local legislation prior to any trial-specific
procedures, sampling, or analyses.
2. Male or female >=18 years old at the time of signature of the ICF.
3. ECOG performance status of 0 or 1.
4. Life expectancy of at least 12 weeks after the start of the treatment
according to the Investigator*s judgement.
5. Patients with radiologically documented disease progression or relapse
during or after all standard of care treatments. Patients who are not eligible
to receive standard of care treatments, and for whom no proven treatments
exist, are eligible.
6. Previous treatment with an anti-PD-1/PD-L1 mAb is allowed as long as the
last administration of the anti-PD-1/PD-L1 mAb on the previous treatment
occurred a minimum of 28 days prior to the first administration of study
treatment.
7. Patient must be willing to participate in the blood sampling for the PK, PD,
and tumor mutation analysis.
8. Adequate organ function defined as all of the following (all screening labs
should be performed locally within 10 days of treatment initiation):
Absolute neutrophil count >=1.5 x 10^9/L (or >= 1.5×10^3/µL or >= 1500/mm^3)
Platelets >=100 x 10^9/L (or >= 100×10^3/µL or >= 100×10^3/mm^3)
Hemoglobin >=8.5 g/dL or >=5.3 mmol/L (red blood cell transfusion allowed to meet
eligibility criteria) or >= 85 g/L
Total bilirubin <= 1.5 times the upper limit of normal (ULN), (patients with
Gilbert*s syndrome, total bilirubin must be <=3 x ULN)
AST and ALT <=2.5 x ULN OR <=5 x ULN for patients with liver metastases
Creatinine <=1.5 x ULN
Patients may enter if creatinine is >1.5 x ULN and estimated glomerular
filtration rate (eGFR) >50 mL/min (assessed by Chronic Kidney Disease
Epidemiology [CKDEPI] Collaboration equation); confirmation of eGFR is only
required when creatinine is >1.5 X ULN
International Normalised Ratio (INR) or Prothrombin Time (PT). Activated
Partial Thromboplastin Time (aPTT) <=1.5 x institutional ULN. Patients taking
low dose warfarin must have their INR
followed closely and according to institutional guidelines.
9. Women of childbearing potential (WOCBP), and men able to father a child must
be ready and able to use two medically acceptable methods of birth control per
ICH M3 (R2) that result in a low failure rate of less than 1% per year when
used consistently and correctly beginning at screening, during trial
participation and until certain time has passed after the last administration
of trial medication:
- Women: 6 months and 12 days after end of BI 907828; 6 months after end of
ezabenlimab.
- Men: 102 days after end of BI 907828; 6 months after end of ezabenlimab.
A list of contraception methods meeting these criteria is provided in the
patient information.
Inclusion criteria 10-14 are only applicable to Phase I a.
The following inclusion criteria are only applicable to Phase I b:
15. At least one target lesion that can be accurately measured per RECIST 1.1.
In patients who only have one target lesion, the baseline imaging must be
performed at least two weeks after any biopsy of the target lesion.
16. Patients with TP53 wild-type status confirmed on tumor tissue.
17. Provision of fresh tissue biopsy at screening (may be omitted if patient
has archival t
Patients must not enter the trial if any of the following exclusion criteria
are fulfilled:
1. Previous administration of BI 907828 or any other MDM2-p53 or MDMX
(MDM4)-p53 antagonist.
2. In Phase Ib (expansion phase) and Phase Ia expansion cohort only: a
documented aminoacid altering mutation in TP53 occurring in the patient*s tumor.
3. Symptomatic brain metastases.
Note: Patients with previously treated brain metastases may participate but
treated lesions should not be used as target lesions.
4. Exclusion criterion 4 is not applicable for patients enrolled after protocol
version 4 is approved.
5. Active bleeding, significant risk of haemorrhage (e.g. previous severe
gastrointestinal bleeding, previous haemorrhagic stroke at any time), or
current bleeding disorder (e.g. haemophilia, von Willebrand disease).
6. Major surgery (major according to the Investigator*s assessment) performed
within 12 weeks prior to start of study treatment or planned within 12 months
after screening (e.g. hip replacement).
7. Any other documented active or suspected malignancy or history of malignancy
within 3 years prior to screening, except appropriately treated basal cell
carcinoma of the skin or in situ carcinoma of uterine cervix, or other local
tumors considered cured by local treatment.
8. Patients who must or wish to continue the intake of restricted medications
(see Section 4.2.2.1) or any drug considered likely to interfere with the safe
conduct of the trial.
9. Currently enrolled in another investigational device or drug trial, or less
than 4 weeks since receiving other investigational treatments. Patients who are
in follow-up/observation for another clinical trial are eligible.
10. Exclusion criterion 10 is not applicable for patients enrolled after
protocol version 4 is approved.
11. Patients who have not recovered from all clinically significant adverse
events from their most recent therapy or intervention prior to study enrolment.
12. Known history of human immunodeficiency virus (HIV) infection.
13. Any of the following known laboratory evidence of hepatitis virus infection:
o Positive results of hepatitis B surface (HBs) antigen
o Presence of HBc antibody together with HBV-DNA
o Presence of hepatitis C RNA
14. Known hypersensitivity to the trial drugs or their excipients.
15. Serious concomitant disease or medical condition affecting compliance with
trial requirements or which are considered relevant for the evaluation of the
efficacy or safety of the trial drug, such as neurologic, psychiatric,
infectious disease or active ulcers (gastro-intestinal tract, skin) or
laboratory abnormality that may increase the risk associated with trial
participation or trial drug administration, and in the judgment of the
Investigator, would make the patient inappropriate for entry into the trial.
16. Chronic alcohol or drug abuse or any condition that, in the Investigator*s
opinion, makes them an unreliable trial patient or unlikely to complete the
trial.
17. Women who are pregnant, nursing, or who plan to become pregnant while in
the trial; female patients who do not agree to the interruption of breast
feeding from the start of study treatment until 6 months and 12 days after last
dose of study treatment.
18. History of (including current) interstitial lung disease or pneumon
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Phase Ib:<br /><br>- Objective response (OR), as assessed by the investigator according to RECIST<br /><br>v. 1.1, measured separately for each cohort. OR is defined as<br /><br>best overall response of confirmed complete response (CR) and/or confirmed<br /><br>partial response (PR) from the start of treatment until the<br /><br>earliest of disease progression (PD), death or last evaluable tumor assessment,<br /><br>and before start of subsequent anti-cancer therapy.<br /><br>- Progression-Free Survival defined as the time from the start of treatment<br /><br>until the earliest of PD or death. Determination of progression is based on<br /><br>objective evaluation per RECIST v. 1.1 by investigators.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Phase Ib:<br /><br>- Objective Response (OR) according to iRECIST as assessed by the investigator.<br /><br>- Disease control (DC) according to RECIST 1.1 and iRECIST as assessed by the<br /><br>investigator.<br /><br>- Overall survival (OS): defined as the time from start of treatment until<br /><br>death from any cause.<br /><br>- Number of patients with DLTs observed during the entire treatment period for<br /><br>each combination treatment.</p><br>